ClinicalTrials.gov
ClinicalTrials.gov Menu

Nicardipine Versus Labetalol During Intubation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01041066
Recruitment Status : Unknown
Verified September 2009 by Seoul National University Bundang Hospital.
Recruitment status was:  Recruiting
First Posted : December 31, 2009
Last Update Posted : December 31, 2009
Sponsor:
Information provided by:
Seoul National University Bundang Hospital

Brief Summary:
The aim of this study was to compare the efficacy of nicardipine and labetalol in attenuation of cardiovascular responses to endotracheal intubation.

Condition or disease Intervention/treatment Phase
Patients Who Are Intubated for General Anesthesia Endotracheal Intubation Drug: labetalol Drug: nicardipine Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Study Start Date : September 2009
Estimated Primary Completion Date : December 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: group L
0.4 mg/kg labetalol
Drug: labetalol
0.4 mg/kg labetalol intravenously 4 min before intubation
Active Comparator: group N
20 ㎍/kg nicardipine
Drug: nicardipine
20 ㎍/kg nicardipine intravenously 4 min before intubation



Primary Outcome Measures :
  1. hemodynamic variables (systolic blood pressure, diastolic blood pressure and mean blood pressure, heart rate) [ Time Frame: preinduction- 10 min after intubation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients scheduled for general anesthesia with endotracheal intubation

Exclusion Criteria:

  • Patients with heart failure or coronary artery disease 2-3 degree atrio-ventricular block or severe bradycardia (< 45 beats/min) asthma, bronchial spasm or chronic obstructive pulmonary disease patients with anticipated difficult intubation (Mallampati class III, IV) severe hepatic or renal dysfunction allergy or contraindication to study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01041066


Contacts
Contact: Jung-Hee Ryu, Ph.D 82-31-787-7497 jinaryu@lycos.co.kr

Locations
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Contact: Jung-Hee Ryu, Ph.D    82-31-787-7497    jinaryu@lycos.co.kr   
Sponsors and Collaborators
Seoul National University Bundang Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT01041066     History of Changes
Other Study ID Numbers: nicardipine-labetalol
First Posted: December 31, 2009    Key Record Dates
Last Update Posted: December 31, 2009
Last Verified: September 2009

Keywords provided by Seoul National University Bundang Hospital:
patients who are intubated for general anesthesia

Additional relevant MeSH terms:
Labetalol
Nicardipine
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Calcium Channel Blockers
Membrane Transport Modulators
Vasodilator Agents